Askal Ayalew Ali, Ph.D.

Assistant Professor Economic, Social, and Administrative Pharmacy
LOCATION: East Wing Pharmacy Building Suite # L1-154O
EMAIL: askal.ali@famu.edu
PHONE: 850-599-3082

EDUCATION
Biosketch

Askal Ayalew Ali, Ph.D., serves as assistant professor, Economic, Social, and Administrative Pharmacy (ESAP).

Currently, Dr. Ali is mentoring four students and serving as dissertation committee members in ESAP and Institute of Public Health students. In 2019 she received a Mini-Medical Marijuana Research and Educational grant from FAMU. The goal of the grant is to measure the knowledge and perceptions of pediatric cancer patient caregivers regarding medical marijuana. She is a co-investigator on 2019 awarded U54-RCMI NIH grant project three entitled: Test Up Now Education Program (TUNE-UP). Her role in the TUNE-UP grant is to examine the cost-effectiveness of a community health advisor’s educational intervention to improve colorectal cancer screening rates among African Americans.

Notable Awards
  • 2017 Teacher of the Year

Research Interest
  • Pharmacoeconomics/health economics

  • Decision modeling, patient satisfaction, and self-rated health status

  • Comparative effectiveness research

  • Patient-centered outcomes research

  • Health disparities research

  • Data collection and evidence synthesis (systemic reviews and meta-analyses)

Selective Publications
  • Diaby, V., Ali, A. A., & Montero, A. J. (2019). Value assessment frameworks in the United States: a call for patient engagement.

  • Ali, A. A., Tawk, R., Xiao, H., Campbell, E., Semykina, A., Montero, A. J., … & Diaby, V. (2019). Comparative effectiveness of radiotherapy for early‐stage hormone receptor‐positive breast cancer in elderly women using real‐world data. Cancer medicine, 8(1), 117-127.

  • Ali, A. A., Xiao, H., Tawk, R., Campbell, E., Semykina, A., Montero, A. J., & Diaby, V. (2017). Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Current medical research and opinion, 33(2), 391-400.

  • Diaby, V., Ali, A. A., Williams, K. J., Ezendu, K., Soto-Perez-de-Celis, E., Chavarri-Guerra, Y., & de Lima Lopes, G. (2017). Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast cancer research and treatment, 166(3), 951-963.

  • Tan, F., Xiao, H., Gummadi, S., Koniaris, L. G., Feldman, J. D., Ali, A., … & Huang, Y. (2017). Impact of body mass index on prognosis for breast cancer patients.

  • Diaby, V., Adunlin, G., Ali, A. A., Zeichner, S. B., de Lima Lopes, G., Kohn, C. G., & Montero, A. J. (2016). Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment, 160(1), 187-196.

  • Diaby, V., Ali, A. A., Adunlin, G., Kohn, C. G., & Montero, A. J. (2016). Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Current medical research and opinion, 32(6), 991-996.

  • Ali, A. A., Xiao, H., Campbell, E. S., & Diaby, V. (2015). Improving health care decision making in the USA through comparative effectiveness research: the role of economic evaluation. Pharmaceutical Medicine, 29(5), 247-253.

  • Diaby, V., Adunlin, G., Ali, A. A., & Tawk, R. (2014). Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast cancer research and treatment, 146(3), 669-673.